Skip to content
About Us
Corporate Profile
Senior Management
Board of Directors
Advisors and EDBI Connect
Core Values
Focal Sectors
Why EDBI
Why EDBI
Impact
Value Creation
Portfolio
News
Contact Us
About Us
Corporate Profile
Senior Management
Board of Directors
Advisors and EDBI Connect
Core Values
Focal Sectors
Why EDBI
Why EDBI
Impact
Value Creation
Portfolio
News
Contact Us
About Us
Corporate Profile
Senior Management
Board of Directors
Advisors and EDBI Connect
Core Values
Focal Sectors
Why EDBI
Why EDBI
Impact
Value Creation
Portfolio
News
Contact Us
Contact us
S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase(HDAC) Inhibitor SB939
27 September 2010
S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939 for the Treatment of Recurrent or Metastatic Prostate Cancer (HRPC)